Categories: Health

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Zevra Therapeutics

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company’s new Chief Financial Officer pursuant to the Company’s 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.

The Company granted Mr. Renz a new hire option to purchase 300,000 shares of Zevra’s common stock. The option has a 10-year term and an exercise price per share equal to $9.55, which was the closing price of Zevra’s common stock on March 18, 2026. The option vests over four years, subject to Mr. Renz’s continued service through the applicable vesting dates.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra’s vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230
jdowns@zevra.com

GlobeNews Wire

Recent Posts

Calidi Biotherapeutics Provides Required NYSE American Disclosure

May 22, 2026 18:00 ET  | Source: Calidi Biotherapeutics, Inc SAN DIEGO, May 22, 2026…

7 hours ago

GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse

Largo, FL, May 22, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by…

7 hours ago

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA,…

7 hours ago

AutoFlight V5000 Matrix Concludes ‘Heterogeneous Three-Aircraft Formation’ Flight, Officially Kicks Off Airworthiness Certification

KUNSHAN, China, May 24, 2026 /PRNewswire/ -- AutoFlight has successfully completed a demonstration flight of…

8 hours ago

C-Lingo: Transforming Chinese Language Learning in Vietnam with AI

HONG KONG, May 24, 2026 (GLOBE NEWSWIRE) -- As economic and cultural exchanges between Vietnam…

18 hours ago

Crypto News Today: AlphaPepe AI DEX Hits 5,000 Users While Bitcoin Price Prediction Eyes $180,000

MONACO, May 23, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

18 hours ago